Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Mechanism of action of factor VIIa in the treatment of coagulopathies.

Hedner, Ulla LU (2006) In Seminars in Thrombosis and Hemostasis 32 Suppl 1(Suppl. 1). p.77-85
Abstract
Recombinant factor VIIa (rFVIIa) has been developed for treatment of bleeding in patients with hemophilia who have inhibitors against factor VIII (FVIII) or FIX, and has been found to induce hemostasis during major orthopedic surgery. The use of rFVIIa treatment for hemophilia is a new concept and is based on the low-affinity binding of FVIIa to the surface of thrombin-activated platelets. Administration of pharmacologic doses of exogenous rFVIIa enhances thrombin generation on the platelet surface at the site of injury independently of the presence of FVIII or FIX. Pharmacologic doses of rFVIIa induce hemostasis not only in hemophilia patients, but also in patients with thrombocytopenia, functional platelet defects, and with profuse... (More)
Recombinant factor VIIa (rFVIIa) has been developed for treatment of bleeding in patients with hemophilia who have inhibitors against factor VIII (FVIII) or FIX, and has been found to induce hemostasis during major orthopedic surgery. The use of rFVIIa treatment for hemophilia is a new concept and is based on the low-affinity binding of FVIIa to the surface of thrombin-activated platelets. Administration of pharmacologic doses of exogenous rFVIIa enhances thrombin generation on the platelet surface at the site of injury independently of the presence of FVIII or FIX. Pharmacologic doses of rFVIIa induce hemostasis not only in hemophilia patients, but also in patients with thrombocytopenia, functional platelet defects, and with profuse bleeding triggered by extensive surgery or trauma. The general mechanism of action of rFVIIa to induce hemostasis under these conditions may be its capacity to generate a tight fibrin hemostatic plug through increased thrombin generation. A tight fibrin plug will aid in resisting the overwhelming local release of fibrinolytic activity triggered by vast tissue damage occurring in extensive trauma. Local fibrinolytic activity also occurs in the gastrointestinal tract as well as during profuse postpartum bleeding. Pharmacologic doses of rFVIIa induce hemostasis in these cases also. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
thrombin, posttraumatic bleeding, generation, bleeding disorders, recombinant factor VIIa, hemophilia
in
Seminars in Thrombosis and Hemostasis
volume
32 Suppl 1
issue
Suppl. 1
pages
77 - 85
publisher
Georg Thieme Verlag KG
external identifiers
  • wos:000237454100009
  • scopus:33646487022
  • pmid:16673269
ISSN
1098-9064
DOI
10.1055/s-2006-939557
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)
id
bfb6c0e0-5bfe-496a-8fec-f755bb2231f8 (old id 157049)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16673269&dopt=Abstract
date added to LUP
2016-04-01 15:29:54
date last changed
2021-06-08 02:36:22
@article{bfb6c0e0-5bfe-496a-8fec-f755bb2231f8,
  abstract     = {Recombinant factor VIIa (rFVIIa) has been developed for treatment of bleeding in patients with hemophilia who have inhibitors against factor VIII (FVIII) or FIX, and has been found to induce hemostasis during major orthopedic surgery. The use of rFVIIa treatment for hemophilia is a new concept and is based on the low-affinity binding of FVIIa to the surface of thrombin-activated platelets. Administration of pharmacologic doses of exogenous rFVIIa enhances thrombin generation on the platelet surface at the site of injury independently of the presence of FVIII or FIX. Pharmacologic doses of rFVIIa induce hemostasis not only in hemophilia patients, but also in patients with thrombocytopenia, functional platelet defects, and with profuse bleeding triggered by extensive surgery or trauma. The general mechanism of action of rFVIIa to induce hemostasis under these conditions may be its capacity to generate a tight fibrin hemostatic plug through increased thrombin generation. A tight fibrin plug will aid in resisting the overwhelming local release of fibrinolytic activity triggered by vast tissue damage occurring in extensive trauma. Local fibrinolytic activity also occurs in the gastrointestinal tract as well as during profuse postpartum bleeding. Pharmacologic doses of rFVIIa induce hemostasis in these cases also.},
  author       = {Hedner, Ulla},
  issn         = {1098-9064},
  language     = {eng},
  number       = {Suppl. 1},
  pages        = {77--85},
  publisher    = {Georg Thieme Verlag KG},
  series       = {Seminars in Thrombosis and Hemostasis},
  title        = {Mechanism of action of factor VIIa in the treatment of coagulopathies.},
  url          = {http://dx.doi.org/10.1055/s-2006-939557},
  doi          = {10.1055/s-2006-939557},
  volume       = {32 Suppl 1},
  year         = {2006},
}